Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs > NorthWest Biotherapeutics (NWBO)

Here is the link to Germany DCVax Clinical

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
john1045 Member Profile
 
Followed By 23
Posts 1,610
Boards Moderated 0
Alias Born 06/09/11
160x600 placeholder
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/19/2014 3:26:04 PM
NW BIO ANNOUNCES FINANCINGS TOTALING $35 MILLION TO EXPAND AND ACCELERATE DCVAX®-L AND DCVAX®-DIRECT PROGRAMS "PR Newswire (US)" - 11/19/2014 3:20:00 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) "Edgar (US Regulatory)" - 11/14/2014 4:02:19 PM
Four Companies to Keep on Your Radar & Special Report on Emerging Beverage Contender by Small Cap IR "InvestorsHub NewsWire" - 11/10/2014 7:00:00 AM
NW BIO MAKING A JOINT POSTER PRESENTATION ON ITS DCVAX-DIRECT TRIAL AT THE 29TH ANNUAL SITC MEETING "PR Newswire (US)" - 11/7/2014 9:15:00 AM
Hot Stocks to Follow for Investment Opportunity & Special Profile "InvestorsHub NewsWire" - 11/6/2014 6:00:00 AM
The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securi... "PR Newswire (US)" - 10/28/2014 2:41:00 PM
DCVAX®-L HOSPITAL EXEMPTION PROGRAM NOW UNDER WAY IN GERMANY "PR Newswire (US)" - 10/14/2014 9:01:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/10/2014 4:31:35 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 10/8/2014 4:11:25 PM
NW BIO ANNOUNCES $11.5 MILLION FINANCING "PR Newswire (US)" - 10/7/2014 9:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/18/2014 9:24:39 AM
NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) "PR Newswire (US)" - 9/16/2014 8:00:00 AM
NW BIO CEO TO PRESENT AT SMi's 3rd ANNUAL CANCER VACCINES CONFERENCE IN LONDON "PR Newswire (US)" - 9/15/2014 8:00:00 AM
NW BIO TO PRESENT UPDATES AT RODMAN RENSHAW 16TH ANNUAL GLOBAL INVESTMENT CONFERENCE "PR Newswire (US)" - 9/8/2014 8:15:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/25/2014 4:26:15 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/19/2014 5:29:40 PM
NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING "PR Newswire (US)" - 8/19/2014 2:44:00 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/15/2014 6:02:42 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) "Edgar (US Regulatory)" - 8/14/2014 4:17:12 PM
NW BIO ANNOUNCES PRICING OF $17.5 MILLION OFFERING OF CONVERTIBLE NOTES "PR Newswire (US)" - 8/14/2014 11:47:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/11/2014 5:17:29 PM
NW BIO OBTAINS APPROVALS FOR ENHANCEMENTS OF PHASE III TRIAL OF DCVAX®-L FOR GBM BRAIN CANCER "PR Newswire (US)" - 8/11/2014 8:15:00 AM
The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securi... "Business Wire" - 7/30/2014 4:45:00 PM
john1045   Monday, 12/24/12 04:47:16 PM
Re: None
Post # of 24735 
Here is the link to Germany DCVax Clinical trials with an area I pasted from long report so they obviously are recruiting over there as of now....

http://translate.google.com/translate?hl=en&sl=de&u=http://www.uniklinik-duesseldorf.de/fileadmin/Datenpool/einrichtungen/universitaetstumorzentrum_id505/neu2012/Dateien/Klinische_Studien_UTZ_Duesseldorf.pdf&prev=/search%3Fq%3Ddcvax%26start%3D50%26hl%3Den%26sa%3DN%26tbo%3Dd%26biw%3D1366%26bih%3D586%26tbs%3Dqdr:w&sa=X&ei=I8nYULiqM7GH0QGx6oDACg&ved=0CGwQ7gEwCTgy

Page 11 of 23

Clinical trials in brain tumors


IND No. 10206

Glioblastoma (brain cancer)

Phase II clinical trial to evaluate DCVax-Brain, autologous dendritic cells pulsed with tumor lysate, for treatment

of glioblastoma multiforme.



A Phase II Clinical Trial Evaluating DCVax-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate for the Treatment of Glioblastoma

Multiforme

Your contact:

Prof. Dr. Michael Sabel

Michael.Sabel @ med.uni-duesseldorf.de



Page 12


Current clinical studies at University Cancer Center UTZ

University Cancer Center UTZ

Info Phone: 0211-8108200

at the University Hospital Dusseldorf

www.uniklinik-duesseldorf.de/utz

Stand: 01/2013

Page 12 of 23

Clinical trials in brain tumors

Fraunhofer Institute

Glioblastoma (brain cancer)

Phase II clinical study evaluating DCVax ®-L Brain autologous dendritic cells loaded with tumor lysate antigen for

Treatment of glioblastoma multiforme (GBM)

Clinical phase II trial to evaluate DCVax ®-L Brain autologous dendritic cells loaded with tumor lysate antigen for treatment of glioblastoma

multiforme (GBM)

Your contact:

Infoline

Tel: 0211-8108200

uta@med.uni-duesseldorf.de


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist